Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections Seattle, Washington March 4-7, 2019 Back

Tweet

New HIV/ART Drugs at CROI 2019       CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS - (03/11/19)   CROI: LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS (03/07/19)   CROI: Monthly injected cabotegravir/rilpivirine noninferior to oral DTG at 48 weeks - Mark Mascolini (03/08/19)   CROI: ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infection (03/08/19)   CROI: Janssen Announces Results Of Two Phase 3 Studies Which Showed Long-Acting Injectable HIV Treatment Regimen Of Rilpivirine And Cabotegravir Demonstrated Comparable Safety And Efficacy To Daily Oral HIV Therapy (03/08/19)   CROI: Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis (03/08/19)   CROI: Efficacy and Safety of the Once-daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ART-naïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results - (03/13/19)   CROI: Efficacy of the Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG+3TC) vs Dolutegravir Plus Tenofovir/Emtricitabine (DTG+TDF/FTC) at W48 in Antiretroviral Naive Women: GEMINI Studies Subgroup Analysis (03/08/19)   CROI: Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Women in the BRIGHTE Study (03/08/19)   CROI: A Phase IIa Study of a Novel Maturation Inhibitor GSK2838232 in HIV patients - (03/15/19)   CROI: IBALIZUMAB: 96-WEEK DATA AND EFFICACY IN PATIENTS RESISTANT TO COMMON ANTIRETROVIRALS - (03/13/19)   CROI: PRO 140 (leronlimab) SC: Long-Acting Single-Agent Maintenance Therapy (SAMT) for HIV-1 Infection - (03/14/19)   CROI: MK-8591 Potency and PK Provide High Inhibitory Quotients at Low Doses QD and QW (03/08/19)   CROI: SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR (03/08/19)   CROI: ACTIVITY OF ECD4-IG AGAINST CCR5 ANTAGONIST-RESISTANT HIV-1 - (03/13/19)   CROI: FAVOURABLE OUTCOME of IN VITRO SELECTIONS WITH NOVEL NRTI PRODRUG GS-9131 - (03/14/19)   CROI: GS-9722: First-in-Class, Effector-Enhanced, Broadly Neutralizing Antibody for HIV Cure - and PGT121 in HIV+ / PGT121 bNAb in HIV+ - (03/15/19)   CROI: THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS - (03/15/19)   more NATAP CROI REPORTS: Conference on Retroviruses and Opportunistic Infections Seattle, Washington March 4-7, 2019